Intellectual Property

InterveXion has exclusively licensed the rights to four issued US patents (6,669,937; 7,202,348; 7,632,929; 7,858,759) and five pending US and international patent applications that cover the anti-METH monoclonal antibody and active vaccine products. The license is granted by the University of Arkansas for Medical Sciences in Little Rock, AR, which also holds a 15% ownership stake in the company.